Scarica l'app Stockscreener
0.000001
9,900%
0.000499
Precedente Chiudi:
$0.0005
Aprire:
$1E-06
Volume 24 ore:
1,615
Relative Volume:
66.00
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-56.94M
Rapporto P/E:
-0.000002
EPS:
-0.4502
Flusso di cassa netto:
$-58.04M
1 W Prestazione:
+9,900%
1M Prestazione:
-87.90%
6M Prestazione:
-95.00%
1 anno Prestazione:
-97.29%
Intervallo 1D:
$0.000001
$0.000001
Intervallo di 1 settimana:
$0.000001
$0.000001
Portata 52W:
$0.000001
$0.000001
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.000001 | 0 | 0 | -56.94M | -58.04M | -0.4502 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-08 | Iniziato | Robert W. Baird | Outperform |
| 2022-04-27 | Iniziato | Evercore ISI | In-line |
Vaxxinity Inc Borsa (VAXX) Ultime notizie
VAXX Stock Crashes 99.5% on NASDAQ: Vaxxinity Inc. Hits Record Low - Meyka
Why Is Vaxxinity, Inc. (VAXX) Stock Down Today? - Meyka
Vaxxinity, Inc.Class A Common Stock (Nasdaq:VAXX) Stock Quote - The Chronicle-Journal
Vaxxinity Inc Stock: Pioneering Synthetic Vaccines in a Competitive Biotech Landscape for North Amer - AD HOC NEWS
VAXX (Vaxxinity) NASDAQ $0.0001 pre-market 27 Mar 2026: Top loser, clinical risk - Meyka
Vaxxinity Inc stock faces Nasdaq delisting risk amid biotech funding crunch - ad-hoc-news.de
VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum - Meyka
Vaxxinity Inc Stock (ISIN: US92239B1035) Faces Uncertainty Amid Biotech Sector Headwinds - AD HOC NEWS
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Analyzing Vaxxinity (NASDAQ:VAXX) and ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Vaxxinity Shares Plummet Amid Extreme Volatility - AD HOC NEWS
Analyzing Vaxxinity (NASDAQ:VAXX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Tangible book value per share of Vaxxinity, Inc. – OTC:VAXX - TradingView
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
VAXX Stock Price, News & Analysis - Stock Titan
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Walgreens
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - Yahoo Finance
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity to voluntarily delist from Nasdaq - Investing.com
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
Vaxxinity reports breakthrough in Parkinson's treatment By Investing.com - Investing.com Australia
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - Yahoo Finance
Lou Reese Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Vaxxinity is brewing up meds for a spacefaring future - Pharma Voice
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology - Citeline News & Insights
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - Stock Titan
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity, Inc. (VAXX) stock price, news, quote and history - Yahoo Finance Singapore
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Molina Rene Paula Net Worth (2025) - GuruFocus
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Walgreens
Anti-amyloid drug shows significant immune response in adults with mild Alzheimer’s - Healio
Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment - Yahoo Finance
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vaxxinity Inc Azioni (VAXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Capitalizzazione:
|
Volume (24 ore):